We announced today that Nidek is cooperating fully with the Food and Drug Administration (“FDA”) to resolve the issues identified in the FDA’s August 2014 warning letter.

President and CEO, Mr. Motoki Ozawa stated, “our response describing our corrective actions will be filed in a timely manner to the FDA. NIDEK is taking action to address the issues adequately and expeditiously to ensure full compliance with FDA requirements. We expect that our corrective actions will result in full resolution of this matter and we will continue to fulfill our role in providing eye care solutions.”